Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05932212 | AK104 for Recurrent or Metastatic Vulvar Cancer | Phase 2 | terminated | Jul 6, 2023 | Akeso | Sponsor decision | Sponsor / business decision |
| NCT03108495 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients… | Phase 2 | terminated | Apr 11, 2017 | Iovance Biotherapeutics, Inc. | After reviewing available safety and efficacy data to date, Iovance concluded the study reached the… | Safety / toxicity |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian… | Phase 1 | terminated | Nov 3, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA… | Phase 1 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05080946 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early Phase 1 | suspended | Oct 18, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Study drug is expiring. Will reopen when new drug is received. | Other (stated, no rule matched) |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | Phase 1 / Phase 2 | suspended | Dec 24, 2020 | University of Chicago | Enrollment Goal Met | Enrollment / accrual |
| NCT04544735 | Improving Women's Function After Pelvic Radiation | N/A | suspended | Sep 10, 2020 | Duke University | Study is suspended due to lack of funds. Will resume as soon as funding is secured. | Funding |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT05458960 | Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate(BASICS) | N/A | terminated | Jul 14, 2022 | Washington University School of Medicine | Staffing issues | Other (stated, no rule matched) |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | Phase 1 / Phase 2 | terminated | Jun 14, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Nov 29, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT06315491 | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | terminated | Mar 18, 2024 | Cybrexa Therapeutics | Limited clinical activity | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid… | Phase 1 | suspended | Apr 12, 2021 | National Cancer Institute (NCI) | Other - Pending amendment. | Other (stated, no rule matched) |
| NCT07173101 | Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on…(HEADBAND) | Phase 2 | terminated | Sep 15, 2025 | University of Utah | Safety Review | Safety / toxicity |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT00799110 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With… | Phase 2 | terminated | Nov 27, 2008 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase… | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Michael McHale | Due to loss of funding | Funding |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in… | Phase 2 | terminated | Jul 23, 2021 | Sun Yat-Sen University Cancer Center | No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding… | Enrollment / accrual |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase 1 / Phase 2 | terminated | Jan 6, 2022 | Genmab | The Sponsor has made a strategic decision to stop the development of GEN1047. | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer… | Phase 1 / Phase 2 | terminated | Dec 24, 2018 | Seagen, a wholly owned subsidiary of Pfizer | Sponsor has decided to stop the trial based on strategic decisions | Sponsor / business decision |
| NCT06666218 | Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) | N/A | suspended | Oct 30, 2024 | Fred Hutchinson Cancer Center | Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to… | Enrollment / accrual |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | Phase 1 | terminated | Apr 19, 2024 | Novartis Pharmaceuticals | Study termination based on sponsor decision due to lack of tolerability observed with… | Sponsor / business decision |
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC… | Phase 1 / Phase 2 | withdrawn | May 4, 2015 | Roswell Park Cancer Institute | opening up at a different site | Other (stated, no rule matched) |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | Phase 2 | terminated | Aug 27, 2020 | University of Maryland, Baltimore | SOC changed and low enrollment | Enrollment / accrual |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With… | Phase 1 / Phase 2 | terminated | Mar 17, 2015 | NewLink Genetics Corporation | Company decision | Sponsor / business decision |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence…(ROMECO) | N/A | withdrawn | Aug 15, 2023 | University Hospital, Tours | feasibility issue | Other (stated, no rule matched) |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian… | Phase 3 | terminated | Jan 28, 2021 | Novartis Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | Phase 2 / Phase 3 | terminated | Apr 7, 2022 | Xiaojun Chen | no enough enrolled patients | Enrollment / accrual |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer… | Phase 2 | terminated | Aug 31, 2022 | University of Oklahoma | Funding issue | Funding |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT03275298 | Evolution of the Therapeutic Care in Ovarian Cancer From 2011(ESME OC) | — | suspended | Sep 7, 2017 | UNICANCER | enrolment temporariliy stopped for budget considerations | Enrollment / accrual |
| NCT05903807 | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer | Phase 2 | terminated | Jun 15, 2023 | Aalborg University Hospital | Early terminated due to low recruitment rate. | Enrollment / accrual |
| NCT07111039 | Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila | N/A | withdrawn | Aug 8, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Lack of funding | Funding |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT07573787 | Homoeriodictyol Sodium Mouthwash to Reduce Chemotherapy Induced Bitter Taste Disorders(HED) | N/A | terminated | May 7, 2026 | Christoph Grimm | slow recruitment during COVID pandemia | COVID-19 / pandemic |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in…(PANEL) | N/A | terminated | Jan 27, 2016 | University Hospital, Rouen | Difficulty in enrolling patients | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials